Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Work at the Cambodia Oxford Medical Research Unit (COMRU) and Angkor Hospital for Children (AHC) has highlighted the importance of melioidosis, infection by the soil-dwelling bacterium Burkholderia pseudomallei, as a cause of severe illness in Cambodian children.

Work at the Cambodia Oxford Medical Research Unit (COMRU) and Angkor Hospital for Children (AHC) has highlighted the importance of melioidosis, infection by the soil-dwelling bacterium Burkholderia pseudomallei, as a cause of severe illness in Cambodian children (P Turner et al and Pagnarith et al).

In October 2017, COMRU will participate in the 2nd Cambodia National Melioidosis workshop, a three day event to improve awareness of Burkholderia pseudomallei infection amongst Cambodian clinicians and laboratory technicians. COMRU’s Miliya Thyl and Soeng Sona will both give presentations at the meeting, alongside director Paul Turner.

To support the workshop’s laboratory sessions, COMRU commissioned a short film in English [above] and Khmer to demonstrate laboratory identification of B. pseudomallei. The video was shot at Angkor Hospital for Children and the microbiology laboratory of the Cambodia Oxford Medical Research Unit. We are very grateful to MORU’s Prof Phaikyeong Cheah and the Wellcome Trust for provision of public engagement funding to support the making of the film.

Cambodia Oxford Medical Research Unit (COMRU)

The Cambodia Oxford Medical Research Unit (COMRU) was established in 2007 as a collaboration between the Angkor Hospital for Children and MORU. The first step in this collaboration was to equip the Angkor Hospital with a microbiological laboratory, and to train the Hospital's technical staff. COMRU are now using this facility to prospectively define the causes of febrile illness and establish susceptibility patterns of common culturable bacterial pathogens. These data will also allow researchers to identify causes of sepsis and sepsis-related death, and will improve diagnosis, treatment and management of paediatric infections in Cambodia. The Mahidol Oxford Tropical Medicine Research Unit (MORU) develops effective and practical means of diagnosing and treating malaria and other neglected diseases such as melioidosis, typhus, TB and leptospirosis.

Mahidol Oxford Tropical Medicine Research Unit (MORU)

MORU was established in 1979 as a research collaboration between Mahidol University (Thailand), Oxford University (UK) and the UK’s Wellcome Trust. MORU’s main office and laboratories are located within the Faculty of Tropical Medicine at Mahidol University in Bangkok, Thailand, with MORU study sites and collaborations across Thailand, Asia and Africa. MORU is generously supported with significant funding from the Wellcome Trust, our major funding partner. We also receive funding from other trusts and foundations, governments, and multi-lateral donors.

Angkor Hospital for Children (AHC)

Renowned Japanese photographer Kenro Izu first visited Cambodia in 1993 to photograph the magnificent Angkor Temples. Cambodia was struggling to emerge from the brutal Khmer Rouge regime, and Kenro was deeply touched by the resilient children he met during his trip. Kenro realized he could not leave Cambodia without doing something for these impoverished children he had seen and captured from behind the lens. He founded a non-profit organization called Friends Without a Border (FWAB) and with the help of the international art community, health care professionals and more than 6,000 supporters from around the world, Angkor Hospital for Children opened its gates in 1999. Today, Claudia Turner is the CEO of the hospital and is an Oxford University Principal Investigator.

Paul Turner (COMRU Director)

Paul Turner is a clinical microbiologist based at the Angkor Hospital for Children in Siem Reap, Cambodia. He is director of the Cambodia-Oxford Medical Research Unit (COMRU).

His research interests include:

  • Antimicrobial resistance surveillance and control;
  • Paediatric healthcare associated infections;
  • Pneumococcal colonisation and disease and the impact of pneumococcal vaccines.

Similar stories

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.

World’s largest clinical trial for COVID-19 treatments expands internationally

EOCRU OCGHR OUCRU OUCRU-Nepal Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.